

there have not been any reports of significant adverse reactions. However, this could be due to reporting bias. Use of the cells and technologies presented here in the regenerative medicine is likely to continue and expand in the near future. The establishment of a safety or adverse effect body, where unexpected clinical outcomes, is encouraged at this time. Until clinical efficacy has been proven, such an institution would, at least, be able to assess whether these procedures “do no harm.”

Safety concerns to consider include, but are not restricted to, aberrant cell development and tissue or vehicle contamination with infectious agents or foreign biological and nonbiological substances used in the laboratory processing of the stem cells.

Secondary to disease should be considered before instituting allogenic-based therapies. Overwhelming cell death of the injected cells could potentially impair tissue repair or, in more severe cases, trigger a significant inflammatory response. Safety considerations of stem cell-based therapies.

The aims to highlight clinical applications for the four areas of research listed above and will address a few key advances and a few of the hurdles yet to be overcome as

the technology and science improve the likelihood that Regenerative Medicine will become clinically routine.

References

1. Curr Opin Organ Transplant. 2009 Sep 24
2. Biotechnol Bioeng. 2009 Aug 28.
3. J R Soc Interface. 2009 Mar 6;6(32):209-32
4. Can Vet J. 2009 Feb;50(2):155-65.
5. Reprod Biol Endocrinol. 2003 Nov 13;1:102
6. Curr Stem Cell Res Ther. 2006 Sep;1(3):345-64
7. Nihon Hotetsu Shika Gakkai Zasshi. 2005 Aug;49(4):563-8.
8. Reprod Biomed Online. 2008 Jan;16(1):70-80.
9. Methods Mol Biol. 2005;300:81-100.
10. J R Soc Interface. 2009 Jun 6;6 Suppl 3:S311-24.
11. Reprod Biomed Online. 2008 Jan;16(1):70-80.
12. Tissue Eng Part A. 2009 Oct 14.
13. Genesis. 2009 Jun;47(6):414-22
14. Dev Dyn. 2008 Aug;237(8):2129-38
15. Tissue Eng Part A. 2009 Oct 14.
16. Tissue Eng Part B Rev. 2009 Oct 13.
17. Biotechnol Prog. 2009 Oct 12.
18. Proc Natl Acad Sci U S A. 2009 Oct
19. http://www.btec.cmu.edu/tutorial/bone_tissue_engineering/bone_tissue_engineering.htm



Acme Biosciences, Inc.

Custom Synthesis
Medicinal Chemistry
Hit confirmation
Lead optimization
Process Research

Intermediates
Building blocks
Reference compounds
Small Libraries
Metabolites

**A Fully Equipped Chemistry CRO
 in the Heart of Silicon Valley**

3941 E Bayshore Road, Palo Alto, CA 94539
 (650)969-8000, info@acmeca.com